Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

N/ACompletedNCT03200977

Bristol-Myers Squibb95 enrolled

Overview

An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.

This study will include a retrospective and prospective observational database analysis.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lymphoma

Interventions

Non-InterventionalOTHER

Non-Interventional

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age greater than or equal to18 years; * First allogeneic HCT for cHL; * Patients with prior autologous HCT for cHL; * Any conditioning regimen, graft source or donor type. * For the primary analysis additional criterion includes prior exposure to nivolumab for treatment of cHL immediately prior to the allogeneic HCT, as defined as nivolumab used alone or in combination with other agents and used as the last line of therapy prior to an allogeneic HCT with the interval between the last dose of nivolumab and start of the conditioning regimen no longer than 12 months. Exclusion Criteria: * Patients with nodular lymphocyte-predominant HL * Previous chimeric antigen receptor T-cell therapy or other genetically modified cellular product

Locations (2)

Local Institution - 0001

Lawrenceville, New Jersey, United States

Center for International Blood and Marrow Transplant Research

Milwaukee, Wisconsin, United States

Outcomes

Primary Outcomes

Treatment-Related Mortality (TRM)

Treatment-Related Mortality at 6 months after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab

Time frame: At 6 months after an allogeneic HCT